Ji Li, PhD Dana-Farber Cancer Institute Basal-like breast tumors comprise a heterogeneous group that accounts for about 15% of all breast cancers. They are highly aggressive and generally fail to respond to targeted therapies. Thus, there is a great need to identify novel vulnerabilities and develop novel therapies for this aggressive breast tumor type. The epithelial-to-mesenchymal […]
Aaron Meyer, PhD Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology Metastatic spread drives the majority of breast cancer mortality and, to do so, requires tumor cells to both disseminate and avoid clearance by the immune system. Inhibiting TAM receptors has shown promising results in models of breast cancer by blocking
Heather Parsons, MD, MPH Dana-Farber Cancer Institute This year, breast cancer will claim the lives of more than 500,000 people worldwide. Most of these will be women in whom the disease has spread to the rest of the body, known as metastatic breast cancer. Women living with metastatic breast cancer typically receive ongoing, single-agent treatments that
Heather Parsons, MD Read More »
